

106. Sixth Interim Revision Announcement Pharmacopeia of the United States, Eighteenth Revision, Nov. 15, 1973.
107. Sanchez, N., L. B. Sheiner, H. Halkin and K. L. Melmon, "Pharmacokinetics of Digoxin: Interpreting Bioavailability," British Medical Journal, pp. 132-134, Oct. 20, 1973.
108. Johnson, F., A. S. E. Fowle, S. Lader, J. Fox and A. D. Munro-Faure, "Biological Availability of Digoxin from Lanoxin Produced in the United Kingdom," British Medical Journal, 4:323-326, 1973.
109. Stoll, R. G., M. S. Christensen, E. Sakmar, D. Blair and J. G. Wagner, "Determination of Bioavailability of Digitoxin Using the Radioimmunoassay Procedure," Journal of Pharmaceutical Sciences, 62, No. 10:1615-1620, 1973.
110. van Oudtshoorn, M. C. B., "Bioavailability of Digoxin," The Lancet, 2:1153, 1972.
111. Smith, T. W. and E. Haber, "Digitalis (First of Four Parts)," The New England Journal of Medicine, 289, No. 8:945-952, 1973.
112. Smith, T. W. and E. Haber, "Digitalis (Second of Four Parts)," The New England Journal of Medicine 289, No. 19:1010-1015, 1973.
113. Smith, T. W. and E. Haber, "Digitalis (Third of Four Parts)," The New England Journal of Medicine, 289, No. 20:1063-1072, 1973.
114. Smith, T. W. and E. Haber, "Digitalis (Fourth of Four Parts)," The New England Journal of Medicine, 289, No. 21:1125-1129, 1973.
115. "Opinions of R. N. Smith, A. D. Muro-Faure, D. A. Chamberlain, T. R. D. Shaw, R. H. Leach, B. F. Johnson, A. C. Caws and D. A. Cowan," The Pharmaceutical Journal, pp. 472-474, Nov. 24, 1973.